BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...BioPharmaceutical Inc. acquired; and Nardi was VP of worldwide manufacturing at Iradimed Corp.Plasma-derived therapeutics company Kedrion S.p.A. hired...
...& Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Kahr...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...sublingual tablet Moderate to severe acute pain PDUFA date 11/3/18 ADMA Biologics Inc. (NASDAQ:ADMA) / Kedrion S.p.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...adults who are candidates for systemic therapy or phototherapy Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion S.p.A....
BioCentury | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

...course of rabies vaccine. Kamada said Kedrab will launch in the U.S. early next year. Kedrion S.p.A....
...commercialize Kedrab in the U.S. Kamada markets the product as KamRab outside of the U.S. Kedrion...
...details, and Kamada did not respond to inquiries. Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Rehovot, Israel Kedrion S.p.A....
BioCentury | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

...course of rabies vaccine. Kamada said Kedrab will launch in the U.S. early next year. Kedrion S.p.A....
...commercialize Kedrab in the U.S. Kamada markets the product as KamRab outside of the U.S. Kedrion...
...inquiries. On Friday, Kamada gained $0.25 to $4.55 on NASDAQ. Jaime De Leon human anti-rabies IgG therapy KamRAB KedRAB Kamada Ltd. Kedrion S.p.A....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...linaclotide Chronic idiopathic constipation (CIC) PDUFA date Early 2017 Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion...
BioCentury | Nov 9, 2016
Clinical News

Human anti-rabies IgG therapy regulatory update

...IgG therapy as post-exposure treatment of rabies infection. The PDUFA date is Aug. 29, 2017. Kedrion...
...Ness Ziona, Israel Product: Human anti-rabies IgG therapy (KamRAB) Business: Infectious Alex Himes human anti-rabies IgG therapy KamRAB Kamada Ltd. Kedrion...
BioCentury | Sep 5, 2016
Clinical News

Human anti-rabies IgG therapy regulatory update

...therapy as post-exposure treatment of rabies infection. The company expects an FDA response in mid-2017. Kedrion...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...Myotonic dystrophy type 1 (DM1) Ph I/II data December Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion...
Items per page:
1 - 10 of 27
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...BioPharmaceutical Inc. acquired; and Nardi was VP of worldwide manufacturing at Iradimed Corp.Plasma-derived therapeutics company Kedrion S.p.A. hired...
...& Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Kahr...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...sublingual tablet Moderate to severe acute pain PDUFA date 11/3/18 ADMA Biologics Inc. (NASDAQ:ADMA) / Kedrion S.p.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...adults who are candidates for systemic therapy or phototherapy Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion S.p.A....
BioCentury | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

...course of rabies vaccine. Kamada said Kedrab will launch in the U.S. early next year. Kedrion S.p.A....
...commercialize Kedrab in the U.S. Kamada markets the product as KamRab outside of the U.S. Kedrion...
...details, and Kamada did not respond to inquiries. Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Rehovot, Israel Kedrion S.p.A....
BioCentury | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

...course of rabies vaccine. Kamada said Kedrab will launch in the U.S. early next year. Kedrion S.p.A....
...commercialize Kedrab in the U.S. Kamada markets the product as KamRab outside of the U.S. Kedrion...
...inquiries. On Friday, Kamada gained $0.25 to $4.55 on NASDAQ. Jaime De Leon human anti-rabies IgG therapy KamRAB KedRAB Kamada Ltd. Kedrion S.p.A....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...linaclotide Chronic idiopathic constipation (CIC) PDUFA date Early 2017 Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion...
BioCentury | Nov 9, 2016
Clinical News

Human anti-rabies IgG therapy regulatory update

...IgG therapy as post-exposure treatment of rabies infection. The PDUFA date is Aug. 29, 2017. Kedrion...
...Ness Ziona, Israel Product: Human anti-rabies IgG therapy (KamRAB) Business: Infectious Alex Himes human anti-rabies IgG therapy KamRAB Kamada Ltd. Kedrion...
BioCentury | Sep 5, 2016
Clinical News

Human anti-rabies IgG therapy regulatory update

...therapy as post-exposure treatment of rabies infection. The company expects an FDA response in mid-2017. Kedrion...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...Myotonic dystrophy type 1 (DM1) Ph I/II data December Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) / Kedrion...
Items per page:
1 - 10 of 27